Merck Sharp + Dohme Corp.

Min Lu

Jared N Cumming

Benjamin Wesley Trotter

Michael D Altman

Ryan D Otte

Andrew M Haidle

James Patrick Jewell

Jongwon Lim

Timothy J Henderson

Matthew Lloyd Childers

Wonsuk Chang

Derun Li

Tony Siu

Brandon D Cash

Matthew A Larsen

Hongjun Zhang

Rui Liang

Anandan Palani

David L Sloman

Brian M Andresen

Abdelghani Achab

Charles A Lesburg

Quang T Truong

Sriram Tyagarajan

Symon Gathiaka

Rachel L Palte

Hua Zhou

Alan B Northrup

Duane E DeMong

Christian Fischer

Matthew J Mitcheltree

Yongxin Han

Alexander Pasternak

Sung-Sau So

Frank W Bennett

Xianhai Huang

Barbara A Pio

Wen-Lian Wu

Liangqin Guo

Solomon D Kattar

Hong Liu

Shawn P Walsh

Gregori J Morriello

Jing Su

Santhosh Francis Neelamkavil

Nunzio Sciammetta

Peter H Fuller

Yi-Heng Chen

Qinglin Pu

Brandon Mitsuo Taoka

John J Acton, Iii

Hakan Gunaydin

David Jonathan Bennett

Vladimir Simov

Kake Zhao

Indu T Bharathan

Brett A Hopkins

Chunrui Sun

Xin Yan

Anmol Gulati

Michael J Ardolino

William P Kaplan

Luis Torres

Kaitlyn Marie Logan

Rebecca Elizabeth Johnson

Mitchell H Keylor

John J Iii Acton

The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.

1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof

Described herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

Arginase inhibitors and methods of use

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors

Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R, R, R, R, R, R, R, A, X, X, and Xare defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.

Aza-benzothiophene compounds as STING agonists

A class of polycyclic compounds of general formula (I), wherein Base, Base, Y, Z, X, X, X, X, X, X, X, X, R, R, R, R, R, R, R, R, R, R, R, R, R, R, and Rare defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.

Cyclic di-nucleotide compounds as sting agonists

Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases. 

Compounds of general formula (I), of general formula (II), of general formula (III), of general formula (IV), of general formula (V), of general formula (VI), and their pharmaceutically acceptable salts, wherein all variables are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer. 

Sting agonist compounds

A class of polycyclic compounds of general formula (I), of general formula (I'), or of general formula (I&#x2033;), wherein Base, Base, Y, Y, X, X, X, X, X, X, X, X, R, R, R, R, R, R, R, R, R, R, R, R, R, and Rare defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds. 

A class of polycyclic compounds of general formula (II), of general formula (II'), or of general formula (II&#x2033;), wherein Base, Base, Y, Y, X, X, X, X, X, X, X, X, R, R, R, R, R, R, R, R, R, R, R, R, R, and Rare defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds. 

Cyclic di-nucleotide compounds as STING agonists

Compounds of general formula (Ia), compounds of general formula (Ia'), compounds of general formula (Ib), compounds of general formula (Ib&#x2032;), compounds of general formula (I), compounds of general formula (I&#x2032;), and their pharmaceutically acceptable salts, wherein R, R, R, R, R, R, R, R, X, X, and Xare defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.

Benzo[b]thiophene compounds as STING agonists

Benzo[b]thiophene compounds as sting agonists

Growing community of inventors

Brookline, MA, United States of America

Min Lu